Ieq Capital LLC Trims Holdings in Novo Nordisk A/S (NYSE:NVO)

Ieq Capital LLC lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 5.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 35,431 shares of the company’s stock after selling 1,855 shares during the period. Ieq Capital LLC’s holdings in Novo Nordisk A/S were worth $3,048,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Freedom Day Solutions LLC grew its holdings in shares of Novo Nordisk A/S by 1.7% in the fourth quarter. Freedom Day Solutions LLC now owns 24,750 shares of the company’s stock valued at $2,129,000 after purchasing an additional 420 shares during the period. Private Wealth Partners LLC boosted its holdings in Novo Nordisk A/S by 48.5% in the 4th quarter. Private Wealth Partners LLC now owns 49,300 shares of the company’s stock valued at $4,241,000 after purchasing an additional 16,097 shares during the last quarter. TBH Global Asset Management LLC grew its stake in shares of Novo Nordisk A/S by 7.2% in the 4th quarter. TBH Global Asset Management LLC now owns 7,492 shares of the company’s stock valued at $644,000 after buying an additional 500 shares during the period. Bryn Mawr Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 358.8% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock worth $3,346,000 after buying an additional 30,420 shares during the last quarter. Finally, Financial Management Network Inc. purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at approximately $248,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on NVO. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an “equal weight” rating for the company. Finally, BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $88.07 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The company has a market cap of $395.19 billion, a P/E ratio of 26.77, a P/E/G ratio of 0.90 and a beta of 0.45. The stock has a 50-day moving average of $86.01 and a two-hundred day moving average of $108.07. Novo Nordisk A/S has a 1-year low of $77.82 and a 1-year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a $0.7874 dividend. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 21.88%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.